Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 19, 2026

Next-Level Creators, Top Media Leaders, Storytelling Legends and AI Step Into the Spotlight As 2026 NAB Show Unveils Latest Speakers, Sessions

View original at globenewswire.com
Next-Level Creators, Top Media Leaders, Storytelling Legends and AI Step Into the Spotlight As 2026 NAB Show Unveils Latest Speakers, Sessions Washington, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- Washington, D.C.— The 2026 NAB Show, taking place April 18–22 (exhibits April 19–22) at the Las Vegas Convention Center, tod…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We're seeing a moment where technology, creativity and business are all evolving at the same time

    60% confidence

  • The 2026 NAB Show lineup is one that truly reflects where the industry is right now: a powerful mix of emerging creators and world-class storytellers alongside the technologies shaping how content is made and delivered

    60% confidence

  • We're seeing that same momentum in our registration, with a significant influx of new voices joining established leaders from across the global media ecosystem

    60% confidence

  • The 2026 NAB Show brings that entire ecosystem together to explore how those changes are shaping the future of storytelling

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com